https://ogma.newcastle.edu.au/vital/access/ /manager/Index ${session.getAttribute("locale")} 5 Quality of life under extended continuous versus intermittent adjuvant letrozole in lymph node-positive, early breast cancer patients: the SOLE randomised phase 3 trial https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:47747 Tue 21 Mar 2023 19:00:49 AEDT ]]> Adjuvant ovarian function suppression and cognitive function in women with breast cancer https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:24211 Thu 28 Oct 2021 13:03:31 AEDT ]]> Fixed-dose-rate gemcitabine combined with cisplatin in patients with inoperable biliary tract carcinomas https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:12335 Sat 24 Mar 2018 08:15:52 AEDT ]]> A phase III randomized trial of high-dose CEOP + filgrastim versus standard-dose CEOP in patients with non-Hodgkin lymphoma: 10-year follow-up data: Australasian Leukaemia and Lymphoma Group (ALLG) NHL07 trial https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:18630 Mon 20 Jul 2015 16:38:11 AEST ]]> Treatment-induced symptoms, depression and age as predictors of sexual problem in premenopausal women with early breast cancer receiving adjuvant endocrine therapy https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:41881 Mon 15 Aug 2022 14:09:04 AEST ]]> Treatment-induced symptoms, depression and age as predictors of sexual problems in premenopausal women with early breast cancer receiving adjuvant endocrine therapy https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:44148 Mon 10 Oct 2022 09:17:25 AEDT ]]>